Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Curr Opin Virol. 2018 Apr;29:79-86. doi: 10.1016/j.coviro.2018.04.001. Epub 2018 Apr 12.
Studies of human infectious diseases have been limited by the paucity of functional models that mimic normal human physiology and pathophysiology. Recent advances in the development of multicellular, physiologically active organotypic cultures produced from embryonic and pluripotent stem cells, as well as from stem cells isolated from biopsies and surgical specimens are allowing unprecedented new studies and discoveries about host-microbe interactions. Here, we summarize recent developments in the use of organoids for studying human viral pathogens, including intestinal infections with human rotavirus, norovirus, enteroviruses and adenoviruses (intestinal organoids and enteroids), neuronal infections with Zika virus (cerebral organoids) and respiratory infections with respiratory syncytial virus in (lung bud organoids). Biologic discovery of host-specific genetic and epigenetic factors affecting infection, and responses to infection that lead to disease are possible with the use of organoid cultures. Continued development to increase the complexity of these cultures by including components of the normal host tissue microenvironment such as immune cells, blood vessels and microbiome, will facilitate studies on human viral pathogenesis, and advance the development of platforms for pre-clinical evaluation of vaccines, antivirals and therapeutics.
人类传染病的研究受到缺乏能够模拟正常人体生理和病理生理学的功能模型的限制。最近,从胚胎和多能干细胞以及从活检和手术标本中分离的干细胞中开发出的多细胞、生理活性的器官型培养物的发展,使得对宿主-微生物相互作用进行前所未有的新研究和发现成为可能。在这里,我们总结了使用类器官研究人类病毒病原体的最新进展,包括人类轮状病毒、诺如病毒、肠病毒和腺病毒的肠道感染(肠道类器官和肠类器官)、寨卡病毒的神经元感染(大脑类器官)和呼吸道合胞病毒的呼吸道感染(肺芽类器官)。利用类器官培养物,有可能发现影响感染和导致疾病的宿主特异性遗传和表观遗传因素的生物学发现。通过包括免疫细胞、血管和微生物组等正常宿主组织微环境的成分来增加这些培养物的复杂性,将有助于研究人类病毒发病机制,并推进疫苗、抗病毒药物和治疗药物的临床前评估平台的发展。